PD 153035 hydrochloride

Key Product Details

Product Description

An extremely potent inhibitor of epidermal growth factor (EGF) receptor tyrosine kinase, with an IC₅₀ of 25 pM. Inhibits other purified tyrosine kinases only at micromolar or higher concentrations.

Licensing Information

Sold with the permission of AstraZeneca UK Ltd.

Product Specifications for PD 153035 hydrochloride

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for PD 153035 hydrochloride

The following data is based on the product molecular weight 396.67.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	25.21 mL	126.05 mL	252.10 mL
0.5 mM	5.04 mL	25.21 mL	50.42 mL
1 mM	2.52 mL	12.60 mL	25.21 mL
5 mM	0.50 mL	2.52 mL	5.04 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 27 publications citing the usage of this product.

• Bridges Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J.Med.Chem. 1996 PMID: 8568816
• Fry A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994 PMID: 8066447
• Bos PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin.Cancer Res. 1997 PMID: 9815602

Product Documents for PD 153035 hydrochloride